PACB Stock Declines Despite Promising HiFi Sequencing Findings

Zacks01-16

Pacific Biosciences of California, Inc. PACB recently announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2503067922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 01:20","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2503067922","market":"us","top_or_hot":-1,"title":"PACB Stock Declines Despite Promising HiFi Sequencing Findings","media":"Zacks","content":"<div>\n<p>Pacific Biosciences of California, Inc. PACB recently announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human...</p>\n\n<a href=\"https://finance.yahoo.com/news/pacb-stock-declines-despite-promising-172000109.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PACB Stock Declines Despite Promising HiFi Sequencing Findings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPACB Stock Declines Despite Promising HiFi Sequencing Findings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-16 01:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pacb-stock-declines-despite-promising-172000109.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacific Biosciences of California, Inc. PACB recently announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human...</p>\n\n<a href=\"https://finance.yahoo.com/news/pacb-stock-declines-despite-promising-172000109.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237957811.SGD","symbol_name":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/pacb-stock-declines-despite-promising-172000109.html","article_id":"2503067922","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503067922","pubTimestamp":1736961600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Pacific Biosciences of California, Inc. PACB recently announced a significant publication from Radboud University Medical Center  and its research partners in theAmerican Journal of Human Genetics.The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple diagnostic tests with a single, more comprehensive approach.Following the announcement, shares of the company moved south 7.9% to $1.85 yesterday. In the past six months, PACB’s shares have lost 11.7% compared with the industry’s decline of 0.8%. The S&P 500 has gained 3.5% in the same time frame.PACB currently has a market capitalization of $575.1 million. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $155.7 million, indicating a 22.4% decline from the reported figure for fiscal 2023.The study highlights HiFi long reads' ability to combine multiple diagnostic tests into a single, ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","BK4566":"资本集团","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4082":"医疗保健设备","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4588":"碎股","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4568":"美国抗疫概念","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","ARAY":"精确射线","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4581":"高盛持仓","MASI":"麦斯莫医疗","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4504":"桥水持仓","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","ABT":"雅培","BK4592":"伊斯兰概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","PACB":"Pacific Biosciences of Californi","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SG9999002232.USD":"Allianz Global High Payout USD","BK4585":"ETF&股票定投概念","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"尽管HiFi测序结果有希望，但PACB股价仍下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARAY":1,"ABT":1,"PACB":1,"MASI":1},"content_text":"Pacific Biosciences of California, Inc. PACB recently announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics.\nThe study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple diagnostic tests with a single, more comprehensive approach.\n(Read more: PacBio Stock May Gain Following the Collaborated Launch of GutID)\nLikely Trend of PACB Stock Following the News\nFollowing the announcement, shares of the company moved south 7.9% to $1.85 yesterday. In the past six months, PACB’s shares have lost 11.7% compared with the industry’s decline of 0.8%. The S&P 500 has gained 3.5% in the same time frame.\nHowever, the news highlights PacBio's HiFi sequencing technology's success in advancing rare disease diagnostics, significantly improving accuracy and detection. This innovation strengthens PacBio's market position in genomics and healthcare, potentially boosting revenues through wider adoption in clinical and research applications. As recognition and demand for such cutting-edge solutions grow, the long-term outlook for PacBio's stock price is positive due to increased investment interest and broader market penetration.\nPACB currently has a market capitalization of $575.1 million. The Zacks Consensus Estimate for fiscal 2024 revenues is pegged at $155.7 million, indicating a 22.4% decline from the reported figure for fiscal 2023.\nImage Source: Zacks Investment Research\nMore on PACB’s HiFi Long-Read Sequencing Study Results\nUnder the direction of Christian Gilissen and Lisenka Vissers of Radboudumc, the study employed HiFi long reads and PacBio's Revio platform to analyze 100 difficult patient samples in which the genetic causes of rare diseases had proven difficult to identify in previous investigations using short reads combined with various supplementary tests. The results of HiFi sequencing from these samples revealed an impressive 93% of pathogenic variants, potentially improving cost-effective diagnostic implementation. HiFi technology also made it possible to detect genetic variants that short-read approaches missed, such as complex structural variants and DNA methylation abnormalities.\nPacBio and Radboudumc are accelerating efforts to integrate HiFi sequencing into clinical practice. In the month-to-date period, 981 samples had been sequenced, with 862 analyzed since August 2024. Automated workflows now process 24 samples per run, with plans to increase to 96, while streamlined protocols aim to support diagnostics for all variant types by summer 2025. Additionally, Radboudumc expanded its Revio instrument fleet in late 2024 to meet the goal of sequencing 5,000 genomes on SPRQ chemistry.\nThe study highlights HiFi long reads' ability to combine multiple diagnostic tests into a single, precise, and comprehensive solution. Researchers expect that ongoing advancements and reduced technology costs will drive its adoption as the preferred approach for diagnosing rare diseases.\nFavorable Industry Prospects for PACB Stock\nPer a report by Grand View Research, the global long-read sequencing market size was valued at $455.1 million in 2022 and is expected to witness a CAGR of 30.9% from 2023 to 2030.\nThe major factors driving the market growth include the rising prevalence of genetic diseases, such as cancers and chromosomal disorders, the rising popularity of personalized medicine and rising technological advancements resulting in the emergence of newer technologies, such as third-generation sequencing.\nPACB’s Zacks Rank & Stocks to Consider\nPACB carries a Zacks Rank #3 (Hold) at present.\nSome better-ranked stocks in the broader medical space are Masimo MASI, Accuray ARAY and Abbott Laboratories ABT.\nMasimo, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 11.8% for 2025. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nMASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 31.7% against the industry’s 1% decline in the past six months.\nAccuray, carrying a Zacks Rank #2 at present, has an estimated growth rate of 1200% for 2025. Its earnings missed estimates in three of the trailing four quarters and met in one, delivering an average negative surprise of 141.97%.\nARAY’s shares have gained 8.8% against the industry’s 1% decline in the past six months.\nAbbott, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 10% for 2025. It delivered a trailing four-quarter average earnings surprise of 1.64%.\nABT’s shares have risen 8.5% in the past six months compared with the industry’s 7.2% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbott Laboratories (ABT) : Free Stock Analysis Report\nAccuray Incorporated (ARAY) : Free Stock Analysis Report\nMasimo Corporation (MASI) : Free Stock Analysis Report\nPacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503067922"}